Endovascular Management of Atherosclerotic Renal Artery Stenosis: Post-Cardiovascular Outcomes in Renal Atherosclerotic Lesions Era Winner or False Alarm?.
- Author:
Evridiki KARANIKOLA
1
;
Georgios KARAOLANIS
;
George GALYFOS
;
Emmanuel BARBARESSOS
;
Viktoria PALLA
;
Konstantinos FILIS
Author Information
- Publication Type:Randomized Controlled Trial ; Review
- Keywords: Renal artery obstruction; Atherosclerosis; Angioplasty; Stents
- MeSH: Angioplasty; Atherosclerosis; Comorbidity; Humans; Hypertension; Kidney Failure, Chronic; Perfusion; Prospective Studies; Renal Artery Obstruction*; Renal Artery*; Retrospective Studies; Stents
- From:Vascular Specialist International 2017;33(1):1-15
- CountryRepublic of Korea
- Language:English
- Abstract: Renal artery stenosis (RAS) is frequently associated with severe comorbidities such as reduced renal perfusion, hypertension, and end-stage renal failure. In approximately 90% of patients, renal artery atherosclerosis is the main cause for RAS, and it is associated with an increased risk for fatal and non-fatal cardiovascular and renal complications. Endovascular management of atherosclerotic RAS (ARAS) has been recently evaluated by several randomized controlled trials that failed to demonstrate benefit of stenting. Furthermore, the Cardiovascular Outcomes in Renal Atherosclerotic Lesions study did not demonstrate any benefit over the revascularization approach. In this review, we summarized the available data from retrospective, prospective and randomized trials on ARAS to provide clinicians with sufficient data in order to produce useful conclusions for everyday clinical practice.
